You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Monday, June 5, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
       
       

      CE

      Sunrise and Skin Cancer: A Look Into LAG-3 Inhibitors for the Treatment of Melanoma

      • Authors: Susan Schneider, PhD, RN, AOCN; Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP; Hussein Tawbi, MD, PhD; Michele Fierstein
      • CE Released: 5/19/2023
      • Valid for credit through: 5/19/2024
      Start Activity

      • Credits Available

        Nurses - 1.25 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

        You Are Eligible For

        • Letter of Completion

      Target Audience and Goal Statement

      This activity is intended for oncology nurses, oncology nurse practitioners (NPs), and other members of the melanoma care team.

      The goal of this activity is for learners to be better able to mitigate potential adverse events (AEs) associated with lymphocyte-activation gene 3 (LAG3) inhibitors as well as leverage the patient voice in the care of patients potentially eligible for or already receiving LAG3 inhibitors for metastatic melanoma.

      Upon completion of this activity, participants will:

      • Have increased knowledge regarding the
        • Safety data associated with LAG-3 inhibitors in metastatic melanoma
        • Strategies used to facilitate shared decision-making (SDM) practices in the care of patients with metastatic melanoma potentially eligible for or already receiving LAG-3 inhibitors
      • Have greater competence related to
        • Mitigating potential adverse events experienced by patients receiving LAG-3 inhibitors for metastatic melanoma
      • Demonstrate greater confidence in their ability to
        • Serve as a trusted liaison between the patient and other members of the melanoma treatment team

      Disclosures

      Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

      All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

      Chair

      • Susan Schneider, PhD, RN, AOCN

        Associate Professor Emerita
        Duke University
        Durham, North Carolina
        ONS Past President

        Disclosures

        Susan Schneider, PhD, RN, AOCN, has no relevant financial relationships.

      Faculty

      • Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP

        Advanced Practice Registered Nurse
        Department of Melanoma Medical Oncology
        The University of Texas
        MD Anderson Cancer Center
        Houston, Texas

        Disclosures

        Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP, has no relevant financial relationships.

      • Hussein Tawbi, MD, PhD

        Professor
        Deputy Chair, Department of Melanoma Medical Oncology
        Co-Director, MD Anderson Brain Metastasis Clinic
        Melanoma Medical Oncology, Investigational Cancer Therapeutics
        The University of Texas
        MD Anderson Cancer Center
        Houston, Texas

        Disclosures

        Hussein Tawbi, MD, PhD, has the following relevant financial relationships:
        Consultant or advisor for: Boxer Capital; Bristol Myers Squibb Company; Eisai Inc.; Genentech; Iovance; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck; Novartis
        Research funding from: Bristol Myers Squibb Company; Dragonfly Therapeutics; Eisai Inc.; EMD Serono; Genentech; GlaxoSmithKline; Merck; Novartis; RAPT Therapeutics

      • Michele Fierstein

        Melanoma patient

        Disclosures

        Michele Fierstein, has no relevant financial relationships.

      Editor

      • Deborah Middleton, MS

        Senior Medical Education Director, Medscape, LLC

        Disclosures

        Deborah Middleton, MS, has no relevant financial relationships.

      Compliance Reviewer/Nurse Planner

      • Stephanie Corder, ND, RN, CHCP

        Associate Director, Accreditation and Compliance, Medscape, LLC

        Disclosures

        Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

      Peer Reviewer

      This activity has been peer reviewed and the reviewer has no relevant financial relationships.

      Accreditation Statements



      In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

        For Nurses

      • Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

        Contact This Provider

      For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

      Instructions for Participation and Credit

      There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

      This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

      Follow these steps to earn CME/CE credit*:

      1. Read about the target audience, learning objectives, and author disclosures.
      2. Study the educational content online or print it out.
      3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

      You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

      *The credit that you receive is based on your user profile.

      From Medscape Education Oncology
      CE

      Sunrise and Skin Cancer: A Look Into LAG-3 Inhibitors for the Treatment of Melanoma

      Authors: Susan Schneider, PhD, RN, AOCN; Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP; Hussein Tawbi, MD, PhD; Michele FiersteinFaculty and Disclosures

      CE Released: 5/19/2023

      Valid for credit through: 5/19/2024

      processing....

      References

      1. American Academy of Dermatology. Skin cancer types: melanoma signs and symptoms. Accessed May 8, 2023. https://www.aad.org/public/diseases/skin-cancer/types/common/melanoma/symptoms
      2. Chung CM, et al. Skin malignancy initially diagnosed as a benign epidermal cyst. Archi Craniofac Surg. 2020;21:123-126.
      3. Cancer.net. Biopsy. Published 2021. Published October 2021. Accessed May 8, 2023. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/biopsy
      4. Huff LS, et al. Defining an acceptable period of time from melanoma biopsy to excision. Dermatol Rep. 2012;4:4-7.
      5. Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208-250.
      6. Woźniak K, et al. Cancer: a family at risk. Menopause Rev. 2014;13:253-261.
      7. Cancer.net. Choosing a doctor for your cancer care. Published March 2021. Accessed May 8, 2023. https://www.cancer.net/navigating-cancer-care/cancer-basics/cancer-care-team/choosing-doctor-your-cancer-care
      8. Balogh EP, et al. Patient-centered cancer treatment planning: improving the quality of oncology care. Summary of an institute of medicine workshop. The Oncol. 2011;16:1800-1805.
      9. American Cancer Society. How treatment is planned and scheduled. Accessed May 8, 2023. https://www.cancer.org/treatment/treatments-and-side-effects/planning-managing/planning-scheduling-treatment.html
      10. Cancer.net. What oncologists think about when recommending a cancer treatment plan. Published March 1, 2022. Accessed May 8, 2023. https://www.cancer.net/blog/2022-03/what-oncologists-think-about-when-recommending-cancer-treatment-plan
      11. National Comprehensive Cancer Network (NCCN). Melanoma cutaneous (Version 3.2022). 2022. Accessed May 8, 2023. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
      12. Eggen AM, et al. Value of screening and follow-up brain MRI scans in patients with metastatic melanoma. Cancer Med. 2021;10:8395-8404.
      13. Switzer B, et al. Managing metastatic melanoma in 2022: a clinical review. J Clin Oncol Pract. 2022;18:335-351.
      14. Kakish HH, et al. Trends in melanoma phase 3 clinical trials since 2010: is there hope for advanced melanoma therapies beyond approved treatment mechanisms? Cancers. 2022;14:1-16.
      15. Tawbi HA, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24-34.
      16. Cancer.net. Melanoma: about clinical trials. Published December 2021. Accessed May 8, 2023. https://www.cancer.net/cancer-types/melanoma/about-clinical-trials
      17. Reynolds RB, et al. The role of advanced practice providers in interdisciplinary oncology care in the united states. Chin Clin Oncol. 2016;5:1-6.
      18. Steinberg H. Oncology nurse coordinators in clinical trials – shaking up the melanoma team. 2020;7:250-254.
      19. Rieger PT. Role of the oncology nurse. In: Kufe DW, et al (eds). 6th ed. Holland-Frei Cancer Medicine; Hamilton (ON): BC Decker;2003.
      20. Palos GR, et al. Patients, family caregivers, and patient navigators. Cancer. 2011;117:3592-3602.
      21. Berry LL, et al. Supporting the supporters: what family caregivers need to care for a loved one with cancer. J Oncol Pract. 2016;13:36-41.
      22. United States Food and Drug Administration. Informed consent for clinical trials. Updated January 4, 2018. Accessed May 8, 2023. https://www.fda.gov/patients/clinical-trials-what-patients-need-know/informed-consent-clinical-trials
      23. Banja JD, et al. Am J Bioeth. Enhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results. 2009;9:39-41.
      24. Mansky C. Navigating uncertainty in immunotherapy regimens. N Engl J Med. 2023;2:1-3.
      25. Brahmer JR, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:1-33.
      26. National Comprehensive Cancer Network (NCCN). Management of immunotherapy-related toxicities (Version 2.2023). 2023. Accessed May 15, 2023. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf
      27. Rauwerdink DJW, et al. Mixed response to immunotherapy in patients with metastatic melanoma. Ann Surg. 2020;27:3488-2497.
      28. Humbert O, et al. Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy. Front Oncol. 2020;10:1-7.
      29. DeBord LC, et al. Social media in dermatology: clinical relevance, academic value, and trends across platforms. J Dermatol Treat. 2018;30:511-518.
      30. Maganty N, et al. Social media as a platform for information and support for melanoma patients: analysis of melanoma facebook groups and pages. JMIR Dermatol. 2018;1:1-5.
      31. Rodin G, et al. Clinican-patient communication: evidence-based recommendations to guide practice in cancer. Curr Oncol. 2009;16:42-49.
      32. Yassine F, et al. Chapter 15 – patient resources in a cancer center. In: Aljurf A, et al (eds). The Comprehensive Cancer Center. The Author(s); 2022;145-155.
      33. Taberna M, et all The multidisciplinary team (MDT) approach and quality of care. Front Oncol. 2020;10:1-16.
      34. Zhang L, et al. Follow-up care for patients receiving immune checkpoint inhibitors. 2021;8:596-603.
      35. Oncology Nursing Society. Voice website. Wiley K. Nursing considerations for melanoma survivorship care. ONS Voice. 2021. https://voice.ons.org/news-and-views/nursing-considerations-for-melanoma-survivorship-care
      « Return to: Sunrise and Skin Cancer: A Look Into LAG-3 Inhibitors for the Treatment of Melanoma
      CE Information
      • Print
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.